Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study

被引:63
作者
Plantinga, Laura C. [1 ]
Fink, Nancy E.
Jaar, Bernard G.
Sadler, John H.
Levin, Nathan W.
Coresh, Josef
Klag, Michael J.
Powe, Neil R.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[3] Independent Dialysis Fdn, Baltimore, MD 21201 USA
[4] Renal Res Inst, New York, NY 10128 USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA
[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA
关键词
D O I
10.1186/1472-6963-7-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Clinical performance targets are intended to improve patient outcomes in chronic disease through quality improvement, but evidence of an association between multiple target attainment and patient outcomes in routine clinical practice is often lacking. Methods: In a national prospective cohort study ( ESRD Quality, or EQUAL), we examined whether attainment of multiple targets in 668 incident hemodialysis patients from 74 U. S. not-for-profit dialysis clinics was associated with better outcomes. We measured whether the following accepted clinical performance targets were met at 6 months after study enrollment: albumin (>= 4.0 g/dl), hemoglobin (>= 11 g/dl), calcium-phosphate product (< 55 mg(2)/dl(2)), dialysis dose (Kt/V >= 1.2), and vascular access type ( fistula). Outcomes included mortality, hospital admissions, hospital days, and hospital costs. Results: Attainment of each of the five targets was associated individually with better outcomes; e. g., patients who attained the albumin target had decreased mortality [ relative hazard ( RH) = 0.55, 95% confidence interval ( CI), 0.41 - 0.75], hospital admissions [ incidence rate ratio (IRR) = 0.67, 95% CI, 0.62 - 0.73], hospital days ( IRR = 0.61, 95% CI, 0.58 - 0.63), and hospital costs ( average annual cost reduction = $3,282, P = 0.002), relative to those who did not. Increasing numbers of targets attained were also associated, in a graded fashion, with decreased mortality ( P = 0.030), fewer hospital admissions and days ( P < 0.001 for both), and lower costs ( P = 0.029); these trends remained statistically significant for all outcomes after adjustment ( P < 0.001), except cost, which was marginally significant ( P = 0.052). Conclusion: Attainment of more clinical performance targets, regardless of which targets, was strongly associated with decreased mortality, hospital admissions, and resource use in hemodialysis patients.
引用
收藏
页数:13
相关论文
共 43 条
[1]   Timing of nephrologist referral and arteriovenous access use: The CHOICE study [J].
Astor, BC ;
Eustace, JA ;
Powe, NR ;
Klag, MJ ;
Sadler, JH ;
Fink, NE ;
Coresh, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (03) :494-501
[2]   Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease [J].
Athienites, NV ;
Miskulin, DC ;
Fernandez, G ;
Bunnapradist, S ;
Simon, G ;
Landa, M ;
Schmid, CH ;
Greenfield, S ;
Levey, AS ;
Meyer, KB .
SEMINARS IN DIALYSIS, 2000, 13 (05) :320-326
[3]   MARKERS FOR SURVIVAL IN DIALYSIS - A 7-YEAR PROSPECTIVE-STUDY [J].
AVRAM, MM ;
MITTMAN, N ;
BONOMINI, L ;
CHATTOPADHYAY, J ;
FEIN, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (01) :209-219
[4]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[5]   UREA INDEX AND OTHER PREDICTORS OF HEMODIALYSIS PATIENT SURVIVAL [J].
COLLINS, AJ ;
MA, JZ ;
UMEN, A ;
KESHAVIAH, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (02) :272-282
[6]  
*COMM MPA, 2005, MED PAYM ADV COMM RE
[7]  
Committee on quality of health care in America-Institute of Medicine, 2001, CROSS QUAL CHASM NEW
[8]  
*CTR MED MED SERV, 2004, 2004 ANN REP END STA
[9]  
DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
[10]  
ELSEVIERS MM, 2003, NEPHROL NEWS ISSUES, V17, P99